Changes in the Use of Hydrochlorothiazide and Other Antihypertensive Drugs in Switzerland in Association With the Swissmedic Safety Alert Regarding Non‐melanoma Skin Cancer: An Interrupted Time‐Series Analysis Using Swiss Claims Data

Abstract

ABSTRACTPurposeLong‐term use of hydrochlorothiazide increases the risk of non‐melanoma skin cancer. We aimed to evaluate potential changes in the use of hydrochlorothiazide in Switzerland after a direct healthcare professional communication (DHPC) in November 2018 by Swissmedic.MethodsWe performed interrupted time‐series analyses using a large Swiss healthcare claims database (2015–2021). Within monthly intervals, we quantified the total number of claims and the total dispensed ‘defined daily doses’ (DDD) for preparations containing (1) hydrochlorothiazide, (2) angiotensin‐converting enzyme (ACE) inhibitors and angiotensin‐II‐receptor blockers (ARB), (3) calcium‐channel blockers (CCB) and (4) thiazide‐like diuretics per 10 000 persons. Using segmented linear regression, we quantified the pre‐DHPC trend, the immediate change and the post‐DHPC change in trend for total claims and DDD for the four drug classes weighted for the demographic distribution of the Swiss population.ResultsACE inhibitors and ARB were the most frequently claimed antihypertensive drugs with 300–400 claims per 10 000 persons, which increased by 5.4% during the study period. The average number of hydrochlorothiazide claims (157/10 000 persons in 2015) declined by 35% between 2015 and 2021. The decrease started prior to the DHPC, but the DHPC was associated with an immediate 6.1% decline and an accelerated decline in claims over time after the DHPC (similar results for DDD). This coincided with a 23% increase in claims of CCB (dihydropyridine type) over 7 years, whereas use of other antihypertensives increased less.ConclusionOur results suggest that the DHPC by Swissmedic in 2018 accelerated a pre‐existing decline in the use of hydrochlorothiazide in Switzerland.